Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)

Royal Brompton & Harefield NHS Foundation Trust1 site in 1 country50 target enrollmentNovember 19, 2018

ConditionsPulmonary Hypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pulmonary Hypertension
Sponsor: Royal Brompton & Harefield NHS Foundation Trust
Enrollment: 50
Locations: 1
Primary Endpoint: Fractions (% area of lung imaged)
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

A prospective study of the use of two novel MRI techniques (oxygen-enhanced and fourier decomposition MRI) in the initial diagnosis and follow-up of patients with Pulmonary Hypertension. The investigators believe these techniques may present a novel set of imaging biomarkers that may be used for risk stratification, prediction of treatment response and longitudinal disease monitoring. The reserach MRI is in addition to standard of care and will not affect treatment decisions.

Registry

clinicaltrials.gov

Start Date

November 19, 2018

End Date

June 2021

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Royal Brompton & Harefield NHS Foundation Trust

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Confirmed diagnosis of Pulmonary Hypertension.
•Age 18 and over.

Exclusion Criteria

•Standard contra-indications to MRI (as per NHS MRI safety questionnaire).
•Not medically fit for transfer to MRI.
•Patient judged inappropriate for involvement in study by clinical team e.g. secondary to emotional burden of recent diagnosis.